SecBot SecBot

ALT

Altimmune, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001326190 Biotech & Drug Discovery
$2.09 −0.03 (−1.65%)
Oct 26 4:00 PM ET · prev $2.12
Market cap
$422.1M
Small cap
Consensus
Buy
87% Buy or better · 15 analysts
Median target
$17.00
+715% · range $11.00–28.00
Next earnings
Nov 10
in 15 days · EPS est. −$0.14
1 year
−49.6%
from $4.14 · Oct 27
30 days
−29.6%
from $2.96
52-week range
$2.09–6.18
at the low
Avg volume 20D
3.61M
shares / day
Short interest
46.08M
≈23.7% of shares · −11.0%
Days to cover
10.5
at average volume
Insider net
+$242.7K
3 buyers · 0 sellers · 12 mo
New fund stakes
3
Q2 2026 13F · 0 exits
SecBot read BULLISH 7 reports · 90 days
Balance 0 bearish · 2 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 6/7 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Altimmune announced positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $242.7K at an average $3.27. No open-market sales. Price is 36% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 58 added (3 new), 11 trimmed or exited. Largest new: Viking Global Investors $20.4M, Ra Capital Management, $19.8M.

  • AnalystsBULLISH

    13 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.167 → −$0.137 over 90 days.

  • Short sellersSTEADY

    Short interest −11.0% to 46.08M shares. 10.5 days to cover, ≈23.7% of shares.

  • TrendDOWNTREND

    28% below its 50-day average. New closing low $2.09 on Oct 26.

  • SocialQUIET

    Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$50.5M
in new stakes
FundMoveSharesValue
BlackRock, Inc.ADD20,385,284$62.0M
STATE STREET CORPADD12,098,540$36.8M
VANGUARD CAPITAL MANAGEMENT LLCADD8,177,752$24.9M
VANGUARD PORTFOLIO MANAGEMENT LLCADD7,330,265$22.3M
MARSHALL WACE, LLPADD6,841,055$20.8M
VIKING GLOBAL INVESTORS LPNEW6,700,000$20.4M
RA CAPITAL MANAGEMENT, L.P.NEW6,500,000$19.8M
GEODE CAPITAL MANAGEMENT, LLCADD5,011,314$15.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 87% rate it Buy or better
Strong Buy4Buy9Hold2Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +715%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 23, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform
Jun 22, 2026Leerink Partners
INITIATE
INITIATEOutperform
May 18, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 14, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Reddit
Crowd this week 60° Warm 1 bullish · 0 bearish
Mentions, 7 days 1 0 in posts · 1 in comments
Recent comments
r/stockmarket Bullish 3d ago
They are buying $ALT
All social signals and their track records

Insider ledger

Form 4
$242.7K
bought · 3 insiders
$0
sold · 0 insiders
−36.3%
vs their $3.27 cost
DateInsiderTypeValue
Oct 1, 2026
MENZIUSO RICHARD THOMAS
Principal Accounting Officer
AWARD36,234 sh
Oct 1, 2026
MENZIUSO RICHARD THOMAS
Principal Accounting Officer
AWARD84,546 sh
Oct 1, 2026
WEAVER GREGORY L
Chief Financial Officer
TAX W/H$12.1K
Oct 1, 2026
WEAVER GREGORY L
Chief Financial Officer
EXERCISE14,475 sh
Oct 1, 2026
Arbet-Engels Christophe
Chief Medical Officer
EXERCISE37,500 sh
Oct 1, 2026
Arbet-Engels Christophe
Chief Medical Officer
TAX W/H$35.0K
Sep 16, 2026
Richardson Linda M
Chief Commercial Officer
EXERCISE24,000 sh
Sep 16, 2026
Richardson Linda M
Chief Commercial Officer
TAX W/H$22.1K

Earnings setup

Estimates
Nov 10
reports in 15 days
−$0.14
EPS estimate, this quarter
+18%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.14-$0.15–-$0.12+0.0%$0.00
Next Q-$0.16-$0.20–-$0.13+0.0%$0.00
Current FY-$0.59-$0.65–-$0.53+0.0%$0.00
Next FY-$0.67-$0.88–-$0.47+0.0%$0.00

Short side

FINRA· Sep 30, 2026
46,079,911
shares short
-11.0%
vs prior settlement
10.5
days to cover
≈23.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 Other
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements
Oct 1, 2026 Insider
MENZIUSO RICHARD THOMAS was granted 36,234 shares
Principal Accounting Officer
Oct 1, 2026 Insider
MENZIUSO RICHARD THOMAS was granted 84,546 shares
Principal Accounting Officer
Oct 1, 2026 Insider
WEAVER GREGORY L surrendered for taxes 4,379 shares
Chief Financial Officer @ $2.76 ($12.1K)
Sep 29, 2026 SEC
Altimmune appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective…
8-K — Impact 2/10
Aug 12, 2026 SEC
Altimmune reported Q2 2026 results with a net loss of $0.12 per share, beating consensus estimates of -$0.13 by 7.7%…
8-K — Impact 5/10
Aug 12, 2026 SEC
Altimmune reported Q2 2026 net loss of $0.12 per share, beating consensus of -$0.13 by 7.7%, but this is a mechanical…
PRESS-RELEASE — Impact 5/10
Aug 3, 2026 Press
Altimmune initiated the PERFORMA Phase 3 registrational trial of pemvidutide in MASH, a key milestone following…
Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
ALT Q3 2026 Earnings Before Market Open — 2026-11-10
Recent
Oct 19, 2026
Press release
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with…
Oct 12, 2026
Trial readout
Results Pending: Pemvidutide (Phase 2) — Completed 74d ago
Trial: RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With…
Sep 8, 2026
Trial readout
Results Pending: Pemvidutide (Phase 2) — Completed 40d ago
Trial: RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With…
Sep 8, 2026
Trial readout
Results Pending: Pemvidutide (Phase 2) — Completed 40d ago
Trial: RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With…
Sep 3, 2026
Press release
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing…

SecBot reports

16 filings · 6 press releases · 2 bullish · 0 bearish · 14 neutral
All ALT filing & press-release reports (22)